纳武利尤单抗联合安罗替尼治疗晚期胃癌患者的疗效及对肿瘤标志物水平的影响  

Efficacy of nivolumab combined with anlotinib in the treatment of advanced gastric cancer patients and its influence on tumor marker levels

作　　者：李韬靖 黎尉浩 LI Taojing;LI Weihao(School of Clinical Medicine,Hubei University of Science and Technology,Xianning 437100,Hubei,China;Department of Gastrointestinal Surgery,Xianning Central Hospital,Xianning 437100,Hubei,China)

机构地区：[1]湖北科技学院临床医学院,湖北咸宁437100 [2]咸宁市中心医院胃肠外科,湖北咸宁437100

出　　处：《癌症进展》2025年第4期390-393,405,共5页Oncology Progress

摘　　要：目的探讨纳武利尤单抗联合安罗替尼治疗晚期胃癌患者的疗效及对肿瘤标志物水平的影响。方法依据治疗方案的不同将80例晚期胃癌患者分为对照组(n=40)和研究组(n=40),对照组患者接受安罗替尼治疗,研究组患者接受纳武利尤单抗联合安罗替尼治疗。比较两组患者的临床疗效、肿瘤标志物[组织多肽特异性抗原(TPS)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平及不良反应发生情况。结果研究组患者的客观缓解率为60.00%,高于对照组患者的25.00%,差异有统计学意义(P﹤0.05)。治疗后,研究组患者血清TPS、CA125、CEA水平均低于对照组,差异均有统计学意义(P﹤0.05)。研究组患者的不良反应总发生率为75.00%,与对照组患者的77.50%比较,差异无统计学意义(P﹥0.05)。结论纳武利尤单抗联合安罗替尼治疗晚期胃癌患者的疗效显著,可有效降低血清肿瘤标志物水平,且安全性较高。Objective To investigate the efficacy of nivolumab combined with anlotinib in the treatment of advanced gastric cancer patients and its influence on tumor marker levels.Method According to different treatment methods,80 patients with advanced gastric cancer were divided into control group(n=40)and study group(n=40).Patients in the control group received anlotinib treatment,while patients in the study group received nivolumab combined with anlotinib treatment.The clinical efficacy,tumor markers[tissue polypeptide specific antigen(TPS),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]levels,and incidence of adverse reactions were compared between the two groups.Result The objective remission rate of the study group was 60.00%,which was higher than 25.00% of the control group,and the difference was statistically significant(P<0.05).After treatment,the serum levels of TPS,CA125,and CEA in study group were lower than those in control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in study group was 75.00%,which was not statistically significant compared to 77.50% in control group(P>0.05).Conclusion The combination of nivolumab and anlotinib has significant efficacy in the treatment of advanced gastric cancer patients,and can effectively reduce serum tumor marker levels with high safety.

关 键 词：纳武利尤单抗 安罗替尼 晚期胃癌 组织多肽特异性抗原 糖类抗原125 癌胚抗原 

分 类 号：R735.2[医药卫生—肿瘤]